English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 17 September 2024, 20:30 HKT/SGT
Share:
    

Source: Ripple Therapeutics
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma

TORONTO, ON, Sept 17, 2024 - (ACN Newswire) - Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.

Ripple's patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing.

"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple Therapeutics. "By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."

Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options are needed to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options.

"At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies," said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with Ripple to further advance the development of RTC-620."

Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.

About Ripple Therapeutics

Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors. www.rippletherapeutics.com

Piper Sandler acted as the exclusive financial advisor to Ripple.

For further information:

Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com, 416-951-7988

SOURCE: Ripple Therapeutics



Topic: Press release summary
Source: Ripple Therapeutics

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Encouraging results expands Kincora Copper and AngloGold Ashanti's First Drilling Program  
Feb 14, 2025 23:09 HKT/SGT
Sadot Group Inc. Announces Appointment of Ms. Catia Jorge as New Chief Executive Officer  
Feb 14, 2025 21:56 HKT/SGT
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025  
Feb 14, 2025 20:00 HKT/SGT
Giftify Deploys Enterprise AI Solutions Driving Operational Excellence and Innovation  
Feb 14, 2025 18:58 HKT/SGT
Maximizing Offshore ROI: Unlocking Financial Success in Global Expansion  
Feb 14, 2025 18:30 HKT/SGT
Mazda to Strengthen Production and Sales Systems in Thailand  
Friday, February 14, 2025 4:04:00 PM
Toyota Develops New Fuel Cell System  
Friday, February 14, 2025 2:27:00 PM
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease  
Friday, February 14, 2025 11:09:00 AM
Graid Technology Announces SupremeRAID SE Support for the NVIDIA GeForce RTX 5000 Series, Expanding High-Performance RAID for Workstations  
Feb 14, 2025 00:00 HKT/SGT
GobizKOREA Online Exhibition Launch: Korean SMEs Unveil Cutting-Edge Products to the Global Market  
Feb 13, 2025 19:40 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575